Skip to main content
. 2020 Oct 21;21:277. doi: 10.1186/s12931-020-01492-z

Table 3.

Treatments and outcomes of COVID-19 patients

Total (n = 252) Non-critically ill (n = 200) Critically ill (n = 52) p value
Treatments
 Antiviral treatment 250 (99.20) 200 (100.00) 50 (96.20) 0.042
 Antibiotics 202 (80.20) 155 (77.50) 47 (90.40) 0.038
 Corticosteroids 28 (11.10) 15 (7.50) 13 (25.00) 0.0003
 Intravenous immunoglobin 11 (4.40) 1 (0.50) 10 (19.20) < 0.0001
 Albumin 7 (2.80) 0 7 (13.50) < 0.0001
 Traditional Chinese medicine 192 (76.20) 160 (80.00) 32 (61.50) 0.005
 Oxygen therapy 200 (79.40) 158 (79.00) 42 (80.80) 0.779
 Mechanical ventilation 10 (4.00) 0 10 (19.20) < 0.0001
 ECMO 4 (1.60) 0 4 (7.70) 0.002
Outcomes
 ARDS 21 (8.40) 1 (0.50) 20 (38.50) < 0.0001
 ICU admission 43 (17.10) 0 43 (82.70) < 0.0001
 Death 6 (2.40) 0 6 (11.50) < 0.0001
 Time from illness onset to dyspnea, days 6 (2.75–9.25) 5.00 (1.50–7.50) 7 (3–10) 0.294
 Time from illness onset to ARDS, days 9 (6.50–13.50) 2 9.50 (7–13.75) 0.137
 Time from illness onset to ICU admission, days 10 (6–18) / 10 (6–18)
  length of hospital stay 17 (14–20) 17 (14–19) 21.50 (17–27.75) 0.001
 Time from hospitalization to death 8.50 (4–12) / 10 (6–18)

Data are median (IQR) or n (%). p values are from χ2 test or Fisher’s exact test, as appropriate. ECMO Extracorporeal membrane oxygenation, ARDS Acute respiratory distress syndrome, ICU Intensive care unit